Platelet Activating Factor and Results of PAF Antagonist Therapy
Platelet activating factor (PAF) is a phospholipid released from cell membranes by the action of phospholipase A2 and it has been implicated in a variety of pathophysiological disorders including acute pancreatitis (1,2). The development of potent PAF receptor antagonists has lead to a greater understanding of the role of PAF in disease processes and the potential for development of these compounds as therapy for inflammatory diseases (3,4). PAF (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) was the term originally introduced for a soluble platelet aggregating substance released from IgE stimulated basophils. PAF is a component of structural membrane lipids and together with other classes of lipid mediators such as arachidonates and leukotrienes, it is involved in the trafficking of membrane phospholipids via transacetylation reactions. PAF is involved in both physiological (fertilisation, foetal development, pressor activity) and pathological processes such as asthma, ischaemia, the systemic inflammatory response syndrome, multiple organ failure and pancreatitis.
KeywordsPlacebo Permeability Superoxide Pancreatitis Amylase
Unable to display preview. Download preview PDF.
- 11.Tomaszewska R, Dembiniski A, Warzecha Z, Banas M, Konturek SJ, Stachura J (1992) Platelet activating factor (PAF) inhibitor (TCV-309) reduces caerulein and PAF-induced pancreatitis. A morphologic and functional study in the rat. J Physiol Pharmacol 4:345–352.Google Scholar
- 21.McKay C, Curran F, Sharpies, Imine CW (1997) A placebo controlled randomised study of lexipafant in severe acute pancreatitis. Br J Surg 84 (in press).Google Scholar
- 22.Toh SKC and The British Acute Pancreatitis Study Group (1997) Lexipafant, a platelet activating factor antagonist, reduces mortality in a randomised placebo controlled study in patients with severe acute pancreatitis. Gut 40 (suppl 1): A12.Google Scholar